Skip to content

Novel drug developmental strategies for treatment‐resistant depression

Éva Borbély, Mária Simon, Eberhard Fuchs, Ove Wiborg, Boldizsár Czéh, Zsuzsanna Helyes

British Journal of Pharmacology November 25, 2021 DOI: 10.1111/bph.15753 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Depression
Keywords Depression economics Drug Pharmacology
Citations 103
Key findings The most promising novel drug targets for treatment-resistant depression are NMDA and mGlu5 receptor antagonists, κ receptor antagonists, and hallucinogenic tryptamine derivates, with S-ketamine being the only registered drug for TRD.

Abstract

Major depressive disorder is a leading cause of disability worldwide. Because conventional therapies are ineffective in many patients, novel strategies are needed to overcome treatment‐resistant depression (TRD). Limiting factors of successful drug development in the last decades were the lack of (1) knowledge of pathophysiology, (2) translational animal models and (3) objective diagnostic biomarkers. Here, we review novel drug targets and drug candidates currently investigated in Phase I–III clinical trials. The most promising approaches are inhibition of glutamatergic neurotransmission by NMDA and mGlu 5 receptor antagonists, modulation of the opioidergic system by κ receptor antagonists, and hallucinogenic tryptamine derivates. The only registered drug for TRD is the NMDA receptor antagonist, S ‐ketamine, but add‐on therapies with second‐generation antipsychotics, certain nutritive, anti‐inflammatory and neuroprotective agents seem to be effective. Currently, there is an intense research focus on large‐scale, high‐throughput omics and neuroimaging studies. These results might provide new insights into molecular mechanisms and potential novel therapeutic strategies.

Comparable studies

Other narrative reviews on depression, most cited first.

Citations in the library

Explore topics